HTA reform gets underway in Australia
Australian Health Technology Assessment (HTA) Review Terms of Reference were released today, and will continue to advocate for bold policy reform to speed up access to innovative medicines.
Commenting on the development, Elizabeth de Somer, chief executive of the pharma trade group Medicines Australia – and newly appointed HTA Review Reference Committee member – said that the release of the Terms of Reference kickstarts the HTA Review process which must deliver equitable, timely, safe and affordable access to innovative medicines for all Australians.
Medicines Australia welcomes changes to the Terms of Reference that strengthen the focus on patients and notes the specific mention of additional groups of Australians who experience access equity issues, such as First Nations people.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze